Back to Archived News
Cytori Receives Patent on Core Celution® System Technology
Monday, June 09, 2008
Five Additional Celution®-Related Patents Received Internationally
San Diego, CA -- Cytori Therapeutics (Nasdaq: CYTX) received Notification of Issuance from the United States Patent & Trademark Office for its core patent covering the Celution® System (USPTO # 7,390,484). This patent protects Cytori’s key device technology, which processes adult stem and regenerative cells from adipose tissue at the patient’s bedside.
"Cytori pioneered the concept of a bedside device to deliver a patient's own adipose derived stem and regenerative cells in a single procedure," said Marc H. Hedrick, M.D., president of Cytori and named inventor on this patent. "We believe the broad claims in the ‘484 patent establish a strong barrier-to-entry against potentially competitive cell processing systems and reinforces our leadership position in regenerative medicine."
The new U.S. patent is a central part of Cytori’s global patent portfolio, which includes more than 150 pending patent applications and five new previously unannounced international patents. The new patents in Korea and Singapore cover Cytori's current Celution® devices. Cytori was also granted patents in Korea and Australia related to the Company's StemSource® Cell Bank. In South Africa, Cytori was granted a patent for using adipose derived stem and regenerative cells in cardiovascular cell therapy.
Celution® 800 is currently being sold into the reconstructive surgery market and the Celution® 900 System is being offered around the globe as part of the Company’s StemSource® Cell Bank. This patent also covers the Celution® family of devices currently in co-development with Cytori’s strategic partner, Olympus Corporation.
"The ‘484 patent is the key foundational patent within our intellectual property portfolio and offers Cytori long-term protection through at least 2024," said Christopher J. Calhoun, chief executive officer of Cytori. "Our patent portfolio works in concert with many other barriers-to-entry to protect all of our target markets for our first-in-class Celution® System."
About Cytori Therapeutics
Cytori Therapeutics' (Nasdaq: CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells. The Celution® 800 System is being introduced in Europe into the reconstructive surgery market while the Celution® 900 System will be launched in Japan and Asia for cryopreserving a patient's own stem and regenerative cells. Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs. (www.cytoritx.com).
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori Therapeutics' Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
Back to Archived News
